ArticleEClinicalMedicine2023

Immunogenicity and safety of SARS-CoV-2 recombinant protein nanoparticle vaccine GBP510 adjuvanted with AS03: interim results of a randomised, active-controlled, observer-blinded, phase 3 trial.

Joon Young Song et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.